We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Blood Test Differentiates Severe COVID-19 from Preeclampsia in Pregnant Women

By LabMedica International staff writers
Posted on 27 Apr 2022
Print article
Image: Blood test can differentiate preeclampsia from severe COVID-19 (Photo courtesy of Pexels)
Image: Blood test can differentiate preeclampsia from severe COVID-19 (Photo courtesy of Pexels)

Preeclampsia is an inflammatory condition that appears during pregnancy and whose cause is still unknown. This condition is characterized by high blood pressure combined with organ dysfunctions, such as renal and liver failure. Should preeclampsia not be early diagnosed, it can lead to serious complications for the mother and the baby. Induced delivery and placenta removal are currently the only solution for this condition. Pregnant women who may have preeclampsia may also be tested positive on COVID-19. In those cases, there may be doubts whether they suffer from preeclampsia and asymptomatic COVID-19 or only have COVID-19 with no preeclampsia, as both pathologies present similar clinical signs. Now, a new study has identified indicators which enable differentiating between both pathologies, thus paving the way for a more accurate diagnosis for both diseases and a better risk assessment.

In the new study, researchers at the Josep Carreras Leukemia Research Institute (IJC, Barcelona, Spain) questioned the extent to which preeclampsia and COVID-19 share biological characteristics. They assessed indicators of endothelial dysfunction, blood clotting, angiogenesis and immune function from blood of pregnant women with preeclampsia or COVID-19 and compared them with of healthy pregnant women’s. The research team were successfully able to differentiate preeclampsia from severe COVID-19, thanks to the strong and reproducible differences in the panel of indicators, being angiogenesis (sFlt-1, Ang2 and P1GF), blood clotting (antigen vWF) and endothelial damage (VCAM-1 and sTNFRI) the most patent.

The study also shows that there are shared elements between both pathologies such as the activation of the complement system, an important part of the immune system, even if the alterations caused by COVID-19 are less significant than the ones caused by preeclampsia. These outcomes are a further step in preeclampsia characterization, a little-known pregnancy-related disease but main responsible for maternal and perinatal mortality in the world and premature births. These results are also medically relevant, as they offer diagnostic tools which allow distinguishing preeclampsia from COVID-19 and helping in their clinical management and treatment. The results of the study are considered as the most important review in gynecology.

Related Links:
IJC 

Gold Supplier
Sample Transport
VACUETTE Transport Line
New
Automatic Immunoassay Analyzer
PATHFAST
New
Washer Dispenser
EL406
New
Molecular Diagnostic System
FlashDetect Flash48

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified 10 new genes linked with hearing loss (Photo courtesy of 123rf.com)

Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. Hearing loss is one of the top contributors... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.